UNAIDS Scientific Expert Panel
2013-2015

Rationale
Scientific evidence and evidence-based action are essential to advance the Joint United Nations Programme on HIV/AIDS (UNAIDS) vision of zero HIV infections, zero discrimination and zero AIDS-related deaths. In light of the rapid pace at which new scientific information is becoming available, the diversity of fields where research evidence is growing rapidly and their potential importance for current policies, UNAIDS is ensuring it has adequate capacity to assess and assimilate the latest scientific developments to inform UNAIDS policies and advance the global AIDS response.

Purpose of the Scientific Expert Panel
To advise UNAIDS on major new scientific discoveries and research evidence, as well as research gaps and strategic AIDS research needs.

Mandate of the Panel
The Panel will be responsible for assessing scientific evidence and providing strategic advice to UNAIDS on the relevance of the research findings. Where appropriate, the Panel will also advise on their relevance to the global AIDS response, particularly in preventing new HIV infections and improving the lives of people living with HIV. The Chair of the Panel will provide advice to the Executive Director of UNAIDS and may be requested to represent UNAIDS as a public spokesperson on scientific matters.

Membership
The Panel will consist of a Chair and at least 30 members but no more than 50 members. A wide range of disciplines, including the broad areas of HIV epidemiology, behaviour, virology, diagnostics, pathogenesis, immunology, treatment, prevention and cure, will be represented on the Panel. Candidate members will be invited by the Executive Director of UNAIDS, Michel Sidibé, to serve on the panel for a 3-year term. The 3-year term may be extended or renewed. Members will serve in their personal capacity and will not be asked to represent their institutions.
42 Scientific experts collaborating together for scientific evidence and evidence-based action to advance the Joint United Nations Programme on HIV/AIDS (UNAIDS) vision of zero HIV infections, zero discrimination and zero AIDS-related deaths
Professor Salim Abdool Karim

Salim S Abdool Karim, MBChB, PhD is a South African clinical infectious diseases epidemiologist who is widely recognised for his research contributions in HIV prevention and treatment.

His contributions to microbicides for HIV prevention spans two decades and culminated in the CAPRISA 004 tenofovir gel trial which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and herpes simplex virus type-2 in women.

He is co-inventor on patents which have been used in several HIV vaccine candidates and his clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients.

Professor Abdool Karim is the recipient of the “TWAS Prize in Medical Sciences” from The World Academy of Sciences (TWAS), the “Olusegun Obasanjo Prize” from the African Academy of Sciences (AAS), the Gold Medal Award from the Academy of Science in South Africa (ASSAf) and the John F. W. Herschel Medal from the Royal Society of South Africa (RSSAf).

He serves on the WHO Expert Panel on Sexually Transmitted Infections and HIV. He is an elected Fellow of the AAS, TWAS, ASSAf, RSSAf and the American Academy of Microbiology. He is a Foreign Associate Member of the Institute of Medicine.
Quarraisha Abdool Karim, PhD is an epidemiologist who has had a profound impact on HIV prevention globally through the CAPRISA 004 study that demonstrated that tenofovir gel prevents both HIV and HSV-2 infection.

This research is the culmination of more than 20 years of research on HIV infection in women, including seminal contributions on the evolving epidemiology and prevention of HIV in women as reflected in her extensive publications several in high impact journals including Science, Nature, Lancet and the New England Journal of Medicine.

Her contributions extend to HIV treatment, where she is a key investigator in the research team that defined when to initiate antiretroviral treatment in TB-HIV co-infected patients that was the basis for the WHO's international policies and guidelines on TB and HIV co-treatment.

In addition to her research, she has contributed to post-graduate training of more than 300 young South African scientists in HIV and TB research through the Columbia University - Southern African Fogarty AIDS International Training and Research Program, which she directs. She has been the recipient of several international and national awards for her scientific contributions the most recent being the being the “Kwame Nkrumah” Science Award from the African Union. She is Vice-President of the African Academy of Science (Southern African Region).
Dr Elaine Abrams

Elaine Abrams, MD, is a Professor of Epidemiology and Pediatrics at Columbia University and the Senior Director for Research at ICAP. At ICAP Dr Abrams leads a large and varied research portfolio that addresses critical scientific questions in HIV prevention, care and treatment.

She is also responsible for the development and implementation of pediatric and perinatal prevention initiatives within ICAP supported programs across sixteen sub-Saharan African countries.

Dr Abrams has been an active investigator in the field of maternal-infant HIV transmission and the natural history of HIV disease in infants, children and youth children since the recognition of the epidemic in the United States.

She developed a comprehensive research and care program for woman and children with HIV infection in Central Harlem, the Family Care Center; has been actively involved in the development of international, national and local guidelines and policies for care and treatment; has conducted multiple studies, clinical trials and implementation science studies in the area of maternal and child HIV.

She is currently the chair of the HIV treatment scientific committee of the NIH funded IMPAACT clinical trials. She also co-chaired the maternal-child health committee of the World Health Organization 2013 HIV guidelines group.

Affiliations
Professor of Epidemiology and Pediatrics: Columbia University
Senior Director for Research: ICAP

Email
eja1@columbia.edu

Primary Areas of Expertise
HIV/AIDS
Epidemiology
Maternal-to-Child Transmission
Françoise Barré-Sinoussi, PhD, has been involved in retrovirology research since the early 1970’s. She is internationally recognized for her discovery of the virus that causes AIDS in 1983.

She has headed up her own laboratory at the Institut Pasteur since 1988 and initiated research programs on viral and host determinants of HIV/AIDS pathogenesis as well as HIV vaccine development using primate models. Her current research is focused on mechanisms required to protect against HIV/SIV infections and/or against early pathogenic signals induced by HIV/SIV.

Dr Barré-Sinoussi has published extensively, including over 270 original publications and more than 120 book chapters. She is a member of a number of French or international scientific committees and societies, including scientific committees of several International AIDS Conferences. In June 2006, Dr. Barré-Sinoussi was elected as a member of the International AIDS Society (IAS) Governing Council in the European Region. She has been an elected member of the French Academy of Science since 2009 and President of the IAS since 2012. She is the recipient of numerous national and international awards, including the Nobel Prize for Medicine in 2008 together with Prof. Luc Montagnier for her contributions to HIV/AIDS. She has been awarded Doctor honoris causa from a number of universities.
Dr Chris Beyrer

Chris Beyrer MD, MPH, is Professor of Epidemiology, International Health and Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health.

He serves as Director of the Hopkins HIV Training Program in Epidemiology and Prevention Science, and founded and directs the Center for Public Health and Human Rights. He is Co-Principal Investigator of the Hopkins Center for AIDS Research (CFAR) and Associate Director of the Hopkins Center for Global Health. He has extensive experience in conducting international collaborative research and training programs in HIV/AIDS, in infectious disease prevention research, HIV vaccine preparedness, and in health and human rights.

Dr. Beyrer served as Field Director of the Thai PAVE and HIVNET studies from 1992-1996, based in Chiang Mai, northern Thailand, and has done extensive research in the epidemiology of HIV among key populations in Thailand, Burma, China, India, South Africa, Malawi, Tanzania, Russia, and Kazakhstan. He is the author of over 200 scientific papers; authored the 1998 book *War in the Blood: Sex Politics and AIDS* in Southeast Asia and co-edited the 2008 book *Public Health and Human Rights: evidence-Based Approaches*. He was appointed President of the IAS in July, 2014 for the next two years.

**Affiliations**
Professor of Epidemiology: Johns Hopkins Bloomberg School of Public Health; The International AIDS Society

**Email**
cbeyrer@jhu.edu

**Primary Areas of Expertise**
HIV Epidemiology and Prevention Sciences
HIV among Key Populations
Public Health and Human Rights
Professor Mark Bower

Mark Bower PhD FRCP FRCPPath, is a medical oncologist at Chelsea & Westminster Hospital and Professor at Imperial College who specialises in the treatment of HIV related malignancies.

He has developed one of the largest centres for the management of these tumours in Europe, receiving referrals from throughout the UK and has cared for over 3,000 patients with HIV-associated cancers.

His clinical research covers the epidemiology, aetiology, pathogenesis and management of these tumours. He has a laboratory programme studying the immunopathology of these tumours in collaboration with a number of basic scientists.

Affiliations
Director: National Centre for HIV associated Malignancy, Chelsea & Westminster Hospital, London
Professor: Imperial College, London

Email
m.bower@imperial.ac.uk

Primary Areas of Expertise
Kaposi’s sarcoma
Non-Hodgkin lymphoma
Non-AIDS defining malignancies
Dr Pedro Cahn

Pedro Cahn, MD, PhD, has been working in infectious diseases for the last 35 years. He is Chief of Infectious Diseases at Fernandez Hospital, Founder and President of Fundacion Huesped (the largest non-governmental organization (NGO) in Argentina devoted to HIV/AIDS), as well as Past President of the International AIDS Society.

He also serves as Professor of Infectious Diseases at the Buenos University. He served as advisor for UNAIDS, WHO, PAHO, UNITAID, MSF, as well as a member of the ARV guidelines panel both for WHO and the IAS-USA and as advisor of the AIDS programs of Argentina, Uruguay, Mexico. He has published more than 180 papers in peer-reviewed journals. He has been awarded as Illustrious Citizen by the House of Representatives of Buenos Aires City in recognition of his trajectory.
ScIENtIfIc ExPER t P ANEllISt

Willard (“Ward”) Cates, Jr., MD, MPH, is President Emeritus and Distinguished Scientist at FHI 360. Before joining FHI 20 years ago, Dr. Cates was at CDC for two decades, where he was in the Family Planning Evaluation Division for half that time and directed the STD/HIV Prevention efforts for the other half. At FHI 360, he has overseen its HIV prevention research and was head of the NIH HIV Prevention Trials Network for 11 years.

Dr. Cates received his undergraduate degree in history from Yale University, a master’s degree in history from King’s College, Cambridge University, a combined MD-MPH degree from Yale School of Medicine, and trained clinically in Internal Medicine at the University of Virginia Hospital. He is board certified in preventive medicine.

Dr. Cates is a Member of the National Academy of Medicine, the American College of Preventive Medicine, and past President of the Society for Epidemiologic Research. Dr. Cates has authored or co-authored over 450 scientific publications. He is co-author of 10 editions of Contraceptive Technology and a past co-editor of Sexually Transmitted Diseases, 2nd edition.

Affiliations

Member: National Academy of Medicine, National Research Council
Fellow: American College of Preventive Medicine
Fellow: Society for Family Planning
Adjunct Professor of Epidemiology: University of Carolina Gillings School of Global Public Health, Chapel Hill, NC
Principal Investigator: USAID Preventive Technologies Agreement
Investigator: NIH Microbicides Trials Network Operations Center

Email
wcates@fhi360.org

Primary Areas of Expertise
HIV prevention
STIs
Family Planning
Professor Marina Cavazzana

Marina Cavazzana, MD, PhD, is a paediatrician, Professor of Haematology since 2000, Director of the Department of Biotherapy at Hospital Necker, University Paris Descartes. She is the Director of the Inserm / Assistance Publique - Hôpitaux de Paris Biotherapy Clinical Investigation Center and leads a research Laboratory, Imagine Institute.

She studied medicine in Padua, Italy and received the degree of Doctor of Medicine in 1983, her certification in Paediatrics in 1987 and a PhD in Life Sciences in 1993 (University Paris VII).

Her main research interests are development of the immune system, genetic diseases of the haematopoietic system and cell and gene therapy. She has initiated several clinical trials based on the use of ex vivo gene modified cells to treat patients with inherited disorders, the preliminary clinical results of which are encouraging. This work was rewarded by the American Society of Haematology (Award on Clinical Research in Gene Therapy in 1999), by the French Academy of Sciences (Special Medical Award in 2000 and Jean-Pierre Lecocq Award on Gene Therapy in 2004). She was awarded the title of Officier de l’Ordre National de la Légion d’honneur in 2011, and given the Irène Joliot Curie 2012 award “Scientific Women of the Year” (Science Academy and French Ministry of Education and Research).
Richard E. Chaisson, M.D. is an infectious disease physician with a special interest in TB and HIV co-infection. He received his BS and MD from the University of Massachusetts and trained in internal medicine, infectious diseases and clinical epidemiology at the University of California, San Francisco.

He was director of the Johns Hopkins AIDS Service from 1988-1998, and he co-founded the Johns Hopkins HIV Clinic cohort. Dr. Chaisson is Founder and Director of the Johns Hopkins Center for Tuberculosis Research, a multidisciplinary institute dedicated to the study of TB from bench to bedside to community. He currently chairs the TB Transformative Science Group of the AIDS Clinical Trials Group and was principal investigator and director of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium assessing the impact of novel strategies for controlling HIV-related TB at the population level. He maintains active collaborative research and training programs in South Africa, Brazil, Malawi, Lesotho and India. In 2011 he assumed leadership of the Johns Hopkins Center for AIDS Research (CFAR), re-establishing and revitalizing a trans-disciplinary program to catalyze innovative HIV research at Hopkins, with a special focus on combatting the Baltimore epidemic. Dr. Chaisson has served on numerous advisory committees for the WHO, CDC, USPHS, NIH and state and local agencies. He has published over 450 scientific papers and book chapters.
Myron S. Cohen, MD, is an infectious disease specialist widely known for his work on transmission and prevention of transmission of HIV.

Dr. Cohen helped to develop laboratory methods to measure HIV in genital secretions, as well as methods to determine the best antiviral agents to reduce replication of HIV in these compartments. Dr. Cohen is the architect and Principal Investigator of the multinational HPTN 052 trial, which demonstrated that antiretroviral treatment of people with HIV infection prevents the sexual transmission of the virus; this work was recognized by Science Magazine as the “Breakthrough of the Year” in 2011.

Dr. Cohen has received the Distinguished Career Award for lifetime achievement in STD/HIV research from the American Sexually Transmitted Diseases Association and the Smadel Award from the Infectious Disease Society of America. Dr. Cohen received the O. Max Gardner from the University of North Carolina System, and the Award for Science from the State of North Carolina, the highest honour in the state. Dr. Cohen is a member of the American Society for Clinical Investigation, the American Association of Physicians and the Institute of Medicine. He is a Fellow of the American Society of Microbiology and the Infectious Disease Society of America.
Hoosen (Jerry) Coovadia, MBBS FCP MSc MD, is an internationally renowned and leading South African researcher in maternal and child health and has led ground-breaking research in mother-to-child transmission of HIV.

He leads a programme of research on maternal, new born and child health, focusing on the implementation of the prevention of HIV transmission from mothers to their infants, maternal health and postnatal care of infants, and the integration of health delivery services. He also contributes to national and global policies on the delivery of effective child health services. He has published extensively on childhood disorders in poor populations, mostly on malnutrition and immunity, infectious diseases, and renal disorders of African and Indian children.

He has also participated in numerous government level policies and programmes on development and poverty and is currently one of 26 Commissioners appointed to the Presidents National Planning Commission in South Africa. He holds the positions of Emeritus Professor of Paediatrics and Child Health and Emeritus Victor Daitz Professor of HIV/AIDS Research, at the University of KwaZulu-Natal, and is Associate Scientific Director at CAPRISA. He is the recipient of numerous prestigious science awards.
Dr Daniel Douek

Daniel Douek, MD, PhD, studied medicine at the Universities of Oxford and London. He then practiced internal medicine, before pursuing a PhD in Immunology at the University of London.

Dr. Douek was appointed to the NIH Vaccine Research Center in November 2000. His laboratory, the Human Immunology Section, studies the processes that determine the course of human diseases in which the immune system, particularly its T-cell arm, plays a central role in their pathogenesis and outcome. He aims to use the knowledge gained to initiate clinical studies of new therapeutic and vaccine approaches. Dr. Douek is a widely published author in the field of human immunology having made significant discoveries in thymic function, immune repertoire diversity, T-cell mediated immunity, mucosal immunology, hematopoietic progenitor cell transplantation and HIV disease pathogenesis. Dr. Douek was given the World AIDS Day Award in 2007, the NIH Director's Award in 2008, and was recognized as one of the world’s top 50 scientists by Scientific American in 2005. He was named as one of the 2012 POZ 100 for his significant contributions to accelerating the end of AIDS.
Wafaa M. El-Sadr, MD, MPH, MPA is a public health researcher and practitioner and an infectious disease specialist. She is a leader in the scale-up of high quality HIV programs around the world.

Through ICAP at Columbia University, the Center she founded, more than 2 million individuals have received access to HIV prevention and care through in-country partnerships. She has led numerous studies that have informed HIV and TB prevention and treatment. She was among the first to highlight the importance of health systems strengthening in the context of the HIV global response, the intersection of HIV and non-communicable diseases and the importance of implementation science in advancing the health of populations.

Dr. El-Sadr was named a MacArthur Foundation fellow and is a recipient of several awards. She was named to the “Guiding 10 Honor Roll” by Scientific American, to the “100 People Who are Changing America” list by the Rolling Stone, as one of “50 Visionaries” by Utne Reader and among “50 Women Who Shaped America’s Health” by Huffington Post. She has received honorary doctoral degrees from Boston University and the American University in Cairo, Egypt.

She serves on the WHO HIV Strategic Technical Advisory Group, is a fellow of the Infectious Diseases Society of America and the American College of Physicians and a member of the Institute of Medicine.
Dr J Peter Figueroa

Dr J Peter Figueroa, OJ, MBBS, DPH, PhD, FFPH is Professor of Public Health, Epidemiology & HIV/AIDS and Director of the Doctorate program in Public Health at the University of the West Indies, Kingston, Jamaica.

He has been an integral part of Jamaica’s progress in health since 1976. As national epidemiologist he developed the disease surveillance system and played a critical role in controlling outbreaks of poliomyelitis, measles, typhoid and malaria. He led Jamaica’s response to the AIDS epidemic for many years and is the Deputy Chair of the Pan Caribbean Partnership against AIDS (PANCAP). He was Jamaica’s Chief Medical Officer between 1997 and 2002. He is the author or co-author of over 130 publications and three books.

He established the Epidemiology Research and Training Unit in Kingston and for 19 years was a scientific secretary of the Caribbean Health Research Council promoting health research throughout the Caribbean. He has conducted numerous consultancies in the Caribbean, East Africa and the Middle East and represented Jamaica at many forums internationally. He is a member of several expert committees including the PAHO Technical Advisory Group (TAG) and WHO Strategic Advisory Group (SAGE) on vaccine preventable diseases. He has numerous awards, including the Order of Jamaica.
Dr Diana Gibb

Diana Gibb, MD, is professor of Epidemiology and Programme Leader of the Paediatric Programme of trials and cohorts at the MRC Clinical Trials unit at UCL London.

Over the last 20 years she set up and coordinated a network of clinical trials and cohorts, across Europe, Thailand and South America mainly addressing questions in paediatric HIV infection. Since 1999 her focus has expanded to Africa where she runs large trials, addressing strategy questions in adult and paediatric HIV infection and more recently in malaria and tuberculosis, collaborating widely with clinical and research centres in 6 countries in East and Southern Africa. Wide interdisciplinary collaboration with health economists, pharmacologists, social and basic scientists and innovators of medicines for children are incorporated into trial programmes. Capacity development is an important feature of the overseas collaborations, including interactive courses in paediatric HIV, on-the-ground training in clinical trials and PhD mentorship. She serves on a number of WHO advisory and guideline committees and continues a clinical commitment at the HIV Family clinic at the Great Ormond Street Hospital for Children in London, which she started in 1991.
Andrew Lofts Gray BPharm MSc (Pharm) FPS FFIP is a pharmacist whose research interests include policy analysis (in particular, the development and implementation of National Medicines Policies), rational medicines use and the application of antiretroviral therapy in resource-constrained settings.

He has been actively involved in the development and assessment of medicines and health-related law in South Africa. He has been a member of the Names and Scheduling Expert Committee of the South African Medicines Control Council since 2000 and was appointed to the South African National Essential Medicines List Committee in 2012. He is a Member of the World Health Organization’s Expert Panel on Drug Policies and Management and has served as a member, rapporteur and co-chairperson of the Expert Committee on the Selection and Use of Essential Medicines. Mr Gray is the associate editor of the South African Pharmaceutical Journal, section editor of the Journal of Pharmaceutical Policy and Practice, and serves on the international editorial advisory boards of the International Journal of Clinical Pharmacy, and the GaBI Journal. Mr Gray is an Honorary Life Member of the Pharmaceutical Society of South Africa, and is currently Chairman of the Board of Pharmaceutical Practice of the International Pharmaceutical Federation (FIP).
Dr Beatriz Grinsztejn

Beatriz Grinsztejn, MD, PhD is an Infectious Diseases physician and researcher at the Evandro Chagas National Institute of Infectious Diseases/Oswaldo Cruz Foundation (FIOCRUZ), in Rio de Janeiro, Brazil. She is the Director of the STD/AIDS Clinical Research Laboratory and Principal Investigator of the HIV Prevention and Therapeutic Clinical Trials Unit at FIOCRUZ, which is the largest and most productive HIV/AIDS research center in Brazil.

For more than 10 years, she has been actively involved in numerous pivotal clinical trials in the field of HIV, including HPTN 052. She is a member of the Brazilian Advisory Committee for Antiretroviral Therapy and HIV/AIDS Research, the WHO 2013 Adult Antiretroviral Therapy Guidelines Panel and the IAS-USA HIV Prevention Panel. She leads a multidisciplinary team focused on Implementation Science, Biomedical prevention for MSM and transgender women, acute infection diagnosis and management, ART strategies, HIV/Tuberculosis and HIV/HPV management. She has dedicated her career to HIV Care and Research and serves as a mentor to clinicians and young investigators in Brazil. She has published more than 150 papers in peer-reviewed journals.

Affiliations
Director: STD/AIDS Clinical Research Laboratory, Evandro Chagas National Institute of Infectious Diseases/Oswaldo Cruz Foundation (FIOCRUZ)

Email
gbeatriz@ipec.fiocruz.br

Primary Areas of Expertise
Antiretroviral Therapy
HIV Prevention
Co-infections
Dr. Ashley Haase

Ashley T. Haase, MD is Regents’ Professor and Head of Microbiology at the University of Minnesota, Minneapolis.

Dr. Haase has devoted the past 30 years of his career to investigating human (HIV-1/AIDS) and non-human primate (SIV) lentivirus infections.

His laboratory is currently investigating the globally predominant sexual route of HIV transmission in the SIV rhesus macaque model with the goal of developing effective vaccines and microbicides.

Dr. Haase was an NIH NINDS Javits Awardee and two-time recipient of an NIH MERIT Award for his work on HIV, and is a member of the Institute of Medicine of the National Academy of Sciences.
James G Hakim, MBChB, FRCP is involved in medical education, HIV/AIDS research, capacity building and programmatic work. He has participated in several studies that have impacted antiretroviral therapy, second-line antiretroviral therapy, antiretroviral therapy for prevention, anti-tuberculosis treatment in HIV/TB co-infection and cryptococcal meningitis treatment in resource limited settings and internationally.

He has authored and co-authored more than 200 peer reviewed articles, abstracts and book chapters. He has been part of several WHO committees that have deliberated on antiretroviral therapy guidelines, adverse events monitoring and laboratory support for successful treatment. He has enthusiastically supported the organization of HIV/AIDS conferences such as CROI, IAS and the Glasgow Drug Therapy Conference. As an active academician he is involved in the training of all cadres of health practitioners in HIV care and research. He is the chair of the Medical Education Partnership Initiative PI Council (August 2014-July 2015) a programme that draws support from PEPFAR and NIH to help improve quality of medical education and strengthen research capacity in HIV/AIDS, TB, Malaria and broader medical education training issues in sub-Saharan Africa.
Richard Hayes, DSc, is a statistical epidemiologist, whose main research interest is in the epidemiology of infectious diseases of public health importance in developing countries. He has a particular interest in the epidemiology and control of HIV, other sexually transmitted infections and tuberculosis.

He is one of the principal investigators of a collaborative programme of research in Mwanza, Tanzania, whose aim is to develop and evaluate preventive interventions against the HIV epidemic. He is also involved in collaborative research on HIV and related infections in other parts of Africa, including Uganda, Zimbabwe, Malawi, Zambia and South Africa. Richard has also conducted research on statistical and epidemiological methods, including work on the design and analysis of cluster-randomised trials, and on transmission models of HIV and other STIs. He is a senior member of the MRC Tropical Epidemiology Group and jointly heads the Biostatistics Core of CREATE, a Gates-funded consortium to evaluate the impact of innovative TB control measures in HIV-endemic populations. He is Principal Investigator of the HPTN 071 (PopART) trial, which will measure the impact of universal voluntary HIV testing and immediate treatment on population-level HIV incidence in Zambia and South Africa.
Pontiano Kaleebu MBchB PhD is a viral immunologist recognized for his contributions to HIV vaccine and HIV molecular epidemiology research in Africa.

He was Chair of the African AIDS Vaccine Programme under WHO/UNAIDS. He has served on a number of committees including the WHO HIV Vaccine Advisory Committee, the founding Global HIV Vaccine Enterprise coordinating committee. He chairs the National HIV Drug resistance working Group and sits on the National ART committee. He is a member of the National Institutes of Allergy and Infectious Diseases (NIAID) HIV/AIDS Clinical Trials Network Strategic Working Group and a member of the CHAVI-Immune Discovery Scientific Advisory Board. The MRC Unit he heads is one of the two MRC-UK Units outside of the UK and is a multidisciplinary Programme studying the HIV epidemic in rural and urban settings including epidemiology, prevention, care, social science and basic science research. He leads the European Developing Countries Clinical Trials Partnership (EDCTP) East African Networks of Excellence. Previous awards include the Joint Third World Academy of Science/Uganda National Council for Science and Technology (TWAS/UNCST) prize for Best Young Scientists in Uganda, an Award from Rotary International for scientific achievements and Fellowship of Imperial College London, Faculty of Medicine.
Eduard Karamov, PhD., DrSc, is involved in retrovirology research since 1985. The first Russian HIV strain was isolated in his laboratory. He supervised the development of first diagnostic tests for HIV, which were widely used in USSR and Russia, and antivirals used for AIDS treatment.

He published over 100 articles in scientific journals and made over 100 presentations at international conferences and symposia. He was a supervisor in fifteen Ph.D. and Dr.Sc. fellowships. His lab served as a probation site for many scientists of the former USSR and Eastern Europe. He was a Member of the Advisory Board of the Russian AIDS Vaccine Program. He is a member of the Vaccine Advisory Committee (VAC) of WHO and of the Editorial Board of the International Journal AIDS and several Russian peer-reviewed journals.

Dr Adeeba Kamarulzaman

Adeeba Kamarulzaman MBBS, FRACP is a Professor of Medicine and Infectious Diseases and presently the Dean of the Faculty of Medicine at the University of Malaya in Kuala Lumpur, Malaysia. She has been at the forefront of Malaysia’s HIV response in both its prevention and treatment programmes and was instrumental in initiating the harm reduction programs in her country.

Through the Centre of Excellence of Research in AIDS which she established at the University of Malaya, she directs and oversees a multidisciplinary HIV research program focusing on key affected populations.

Dr Kamarulzaman is presently Co-Chair of WHO’s Strategic and Technical Advisory Committee on HIV and is a Governing Council member of the IAS. She was the Co-Chair of the the VIIth IAS Conference on Pathogenesis, Treatment and Prevention that was held in Kuala Lumpur in 2013.

Affiliations
Dean & Professor: Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Director: Centre of Excellence for Research in AIDS (CERiA), University of Malaya
Adjunct Professor: Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, New Orleans, USA
Adjunct Associate Professor: Yale School of Medicine, Yale University, USA

Primary Areas of Expertise
HIV prevention and treatment for people who use drugs
HIV-TB co-infection
Key affected populations

Email
adeeba@ummc.edu.my
Elly Katabira, MD has been member of the teaching faculty of Makerere University College of Health Sciences since 1985 as well as Consultant Neurophysician to Mulago Hospital, the Makerere University Teaching Hospital.

During this period he has worked in the field of HIV/AIDS as well as a clinician, educator and researcher. He has also been member of the International AIDS Society since 1990 and a member of the governing council since 2000. In 2008 he became President Elect and in July 2010 he took over the presidency of IAS until July 2012.

He was the International Chair for the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention that took place in Rome July 17-20, 2011 and also the International Chair for the International AIDS Conference in July 2012 in Washington DC. He has been involved in a number of studies, including clinical trials in the field of HIV for the last 20 years in his institution in Uganda, including being a site Principal Investigator in a multi-site clinical trial (PrEP) among discordant couples in collaboration with Washington University, Seattle.

**Affiliations**

**Professor of Medicine:** School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda

**Immediate Past President:** International AIDS Society

**Email**
katabira@imul.com
ekatabira@chs.mak.ac.ug

**Primary Areas of Expertise**

HIV Care
HIV Prevention research
HIV and Neurological complications
Dr Karine Lacombe

Karine Lacombe, MPH, PhD, is currently holding the position of associate professor in the infectious and tropical diseases department of Saint-Antoine Hospital (AP-HP), Paris – France.

She teaches infectious diseases and public health in numerous universities and schools around France, Sub Saharan Africa and the Asian continent. She is involved in the clinical and therapeutic management of HIV-infected patients care at the inpatient and outpatient clinic of the hospital.

As part of her academic work, she developed clinical research in Europe, Sub-Saharan Africa and Vietnam on the issues of HIV-chronic hepatitis B and C, as well as co-morbidities associated with the use of antiretrovirals. She is the main authors of over 70 peer-reviewed publications and books on these subjects. She has an MPH in public health and evaluation of health actions and a PhD in epidemiology obtained at the Pierre et Marie Curie University of Sciences, in Paris.
Dr. Sandra Nusinoff Lehrman

Sandra Nusinoff Lehrman MD, trained as a pediatric infectious diseases specialist at Massachusetts General Hospital and Duke University.

Beginning in 1983 she embarked on a career in antiviral drug development including work on acyclovir, AZT, FTC and raltegravir and other antivirals during tenures at Duke, Burroughs Wellcome, Triangle Pharmaceuticals and Merck & Co. She is the co-inventor of several patents. Dr. Lehrman served as the Director of the Therapeutic Research Program at the Division of AIDS, NIAID from 2003 to 2007. Prior to that she was the CEO and President of Genzyme Transgenics.

Dr. Lehrman is a member of IDSA, HIVMA and IAS and currently serves as the industry Co-Chair for the IAS Industry Liaison Forum and also as industry Co-Chair for the Forum for Collaborative HIV Research. She also is a member of the President’s Advisory Council for Biology and Medicine at Brown University.

Affiliations
Executive Director: Global Director of Scientific Affairs – HIV, Office of the Chief Medical Officer, Merck & Co, North Wales, PA 19454

Email
Sandra_lehrman@merck.com

Primary Areas of Expertise
HIV Treatment
HIV/HCV Co-infection
Pediatric HIV infection
Professor Sharon Lewin, FRACP, PhD, is an infectious diseases physician and basic scientist. She is Director of the Department of Infectious Diseases at The Alfred Hospital and Monash University and co-head of the Centre for Biomedical Research, Burnet Institute, Melbourne, Australia.

She completed her medical degree and PhD at Monash University, Melbourne and her post-doctoral fellowship at Rockefeller University, New York with Professor David Ho. Her laboratory focuses on understanding how HIV persists in patients on antiviral therapy, strategies to cure HIV infection and how the immune system recovers following antiviral therapy.

She is a past president of the Australian Society for HIV Medicine (2005-2007) and a member of the Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmitted Infections, the peak advisory body on HIV-related issues to the Australian government. She is the local co-chair for the XXth International AIDS Conference (AIDS2014) which was held in Melbourne July 2014.
Jean-Paul Moatti, PhD, is Professor of Health Economics at Aix-Marseille University (France). He has been involved in AIDS research as early as 1985, concentrating his work in developing countries since 1998, and being one of the first economists to argue in favour of universal access to antiretroviral treatment for HIV/AIDS.

He is currently member of the Board of Aix-Marseille University and Director of SESSTIM, the only economic and social science research unit in France which is nationally supported by both INSERM (the French NIH) and IRD (the public research organisation for developing countries in France).

During the last three years, he was the Director of the French Public Health Institute (ISP) from the Alliance for health and life sciences (AVIESAN) which coordinates all publicly funded health and biomedical research in France. He has been Vice-Chair of Scientific Advisory Board of INSERM (2008-11), Chair of the Public Health Committee for the French Agency for AIDS and hepatitis research (ANRS) (2000-2007) and a former member of the Advisory Committee for Health Research for the ED of WHO (2004-2010). He has also been Adviser to the ED of the Global Fund to fight AIDS, TB and Malaria (2007-8). He published more than 400 papers in scientific journals.
Ademola Olajide, MD is a national of Nigeria and a Medical Doctor by profession with a specialization in public health.

He has over the last decade been actively engaged in the promotion of reproductive health and rights at the local, national, and now at the continental level. Following a stint both with the private for-profit and private not-for-profit (CSOs) sectors, he has served the United Nations Population Fund at different times as State Programme Adviser, Reproductive Health Adviser, and National Programme Officer. This has included responsibilities for the implementation of the fund’s support to the maternal health programme of Africa’s most populous nation.

He has also served UNICEF as an HIV Specialist and the African Union Commission as Head of Division, Health, Nutrition and Population, providing technical leadership to the Commission’s agenda to promote health which includes the implementation of the Pharmaceutical Manufacturing Plan for Africa (PMPA) and its Business Plan.

Dr. Olajide currently serves the UNFPA as Representative to Namibia. Dr. Olajide, in addition to a Masters in Public Health, possesses a Masters in Business Administration as well as a Masters in International Relations and Strategic Studies, thus bringing to bear diverse but relevant perspectives to addressing health issues.
Dr. Praphan Phanuphak, MD, PhD, is Professor Emeritus of Chulalongkorn University in Bangkok, member of the Thailand National AIDS Committee (NAC) and Chair of the HIV Biomedical Prevention Subcommittee.

He directs the operation of Thailand’s first VCT centre in Bangkok, the Thai Red Cross Anonymous Clinic. The Clinic is very popular among MSM/TG with the added services of STI and anal PAP smear screenings. The VCT service is now extending into the community by helping communities to set up community-based and community-led VCT for MSM/TG. Professor Phanuphak is a co-Director of HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Asia’s first HIV clinical trials centre. HIV-NAT is well known internationally for its high impact clinical research.

Professor Phanuphak is a strong advocate of combination antiretroviral therapy for preventing mother-to-child transmission in Thailand and the region. He is also a strong advocate for treatment as prevention or earlier initiation of ART. The new 2014 Thai HIV Treatment Guidelines recommends starting ART at any CD4 levels. Thai Red Cross AIDS Research Centre, together with the Ministry of Public Health and other partners are now conducting a Test and Treat project for MSM/TG in Bangkok and several provinces in Thailand.
Jean Pape, MD, from Haiti, is an internationally recognized infectious diseases expert. In 1980 he joined the Cornell faculty and introduced in Haiti new guidelines for the care of children with diarrhea resulting in a decrease of hospital mortality from 40% to <1%.

His most important scientific accomplishment is the recognition and first comprehensive description of AIDS in the developing world. In 1982, he founded GHESKIO, the first institution in the world dedicated to the fight against AIDS. He has been unrelenting in his efforts to implement programs for the prevention and control of AIDS and TB in resource-poor countries. He is recognized for the 50% decrease in the national infantile mortality and the similar decrease in the national HIV seroprevalence.

He currently directs NIH-supported clinical trials in Haiti as well as the largest AIDS and TB treatment centers in the Caribbean. In 2010, he led GHESKIO's response to the catastrophic earthquake and the major cholera epidemic including the successful introduction of oral cholera vaccine. Dr. Pape is the recipient of numerous awards including: the French "Legion d'Honneur," election to the Institute of Medicine, Carlos Slim Heath Research, Gates Global Health, Clinton Global Initiative, TB Kochon and Haiti's highest award “Honneur et Mérite Grade Commandeur “.

Affiliations
Professor of Medicine: Weill Cornell Medical College, NY, USA
Director: Centres GHESKIO, Port-au-Prince, Haiti

Email
jwpape@gheskio.org

Primary Areas of Expertise
AIDS
Tuberculosis
Peter Reiss, MD, PhD is Professor of Medicine at the Academic Medical Center in Amsterdam where he holds a joint appointment in the Department of Global Health and the division of Infectious Disease.

Dr. Reiss also serves as Director of the Netherlands HIV Monitoring Foundation, and serves on the Scientific Advisory Boards of the Agence Nationale de Recherches sur le Sida et les hépatites (ANRS) and the Swiss HIV Cohort Study, the Steering Committees of the D:A:D study, the ART-Cohort Collaboration and the EuroSida Study. He is one of the four rotating scientific coordinators of EuroCoord.

He is Clinical HIV Section Editor for Antiviral Therapy and editorial board member of a number of other journals. Dr. Reiss also is immediate past President of the European AIDS Clinical Society, and is the European & Central Asian regional representative on the Governing Council of the International AIDS Society (IAS) (until July 2014). His current research focusses particularly on the complications of HIV and HIV treatment, and more particularly in relation to ageing.
Dr Suniti Solomon, a clinical microbiologist, documented the first evidence of HIV in India (1986) and is globally recognized for establishing a proven continuum of care model at Chennai, India, and for her pioneering work in HIV research.

She has contributed to and has served as a lead investigator on research studies including the NIMH Multisite HIV/STD prevention trial, the HPTN 052 Protocol and the Conrad CS gel phase III microbicide trial.

She has received four life time achievement awards in India, a Honorary Doctoral Degree (DMS) from the Brown University, USA, and the National Women Bio-scientist award. She has also been recognized by several awards for her education and humanitarian services.

She serves as a member on the National Technical Team on Women and AIDS in India, the advisory board of the International AIDS Vaccine Initiative, India, and the International HIV/AIDS Alliance, India, the Microbicide committee of the Indian Council of Medical Research and on the Asia Data Safety Monitoring Board of the Division of AIDS, NIAID. She is also a member of the Planning Group for Research in International Settings.

**Affiliations**

**Director:** YR Gaitonde Centre for AIDS Research and Education (YRG CARE)  
**Managing Trustee:** YR Gaitonde Medical, Educational and Research Foundation

**Email**

suniti@yrgcare.org

**Primary Areas of Expertise**

HIV Care Continuum  
Validation of low-cost assays  
Women and AIDS
Dr Papa Salif Sow

Papa Salif Sow, MD, trained as a physician and specialized in infectious and tropical diseases. Since 1987, Dr Sow has worked extensively in the field of infectious diseases in general and HIV/AIDS in particular in terms of care patients, teaching and research.

He has focused his research on the development on diagnosis and treatment of opportunistic infections and on first line antiretroviral therapies and management strategies in resources limited countries. As the Head of the Department of Infectious Diseases of the University of Dakar, he was leading the Senegalese Initiative for Access to ARV and coordinate a multidisciplinary team for scaling up this strategy in the country.

He was member of the WHO Writing Guidelines Group for Access to Care and Treatment in Resource Limited Settings, member of the Strategic Advisory Committee for HIV/AIDS and he is also a member of the Technical Review Panel of the GFATM during Round 4, 5, 6 and 7. He has many research collaboration mainly with the ANRS in France and the University of Washington Seattle (USA) focus on opportunistic infections cervical dysplasia and HIV therapies. His research interests included also second line ARV therapies in resources limited countries and HPV vaccine trial in young girls.

Affiliations
Professor: Department of Infectious Diseases
University of Dakar, Senegal
Senior Program Officer: Global Health Program, HIV - Bill and Melinda Gates Foundation
Member: Governing Council for the Africa region of the IAS
Member: Senegalese National Academy of Science

Email
papasalifsow@gmail.com
Salif.Sow@gatesfoundation.org

Primary Areas of Expertise
Management Opportunistic infections
First and second line ART
Measuring and improving adherence to medication
Dr Soumya Swaminathan

Soumya Swaminathan, MD, is a pediatrician by training, having completed her medical education at the Armed Forces Medical College and the All India Institute of Medical Sciences (India) followed by a fellowship in pediatric pulmonology at the Children’s Hospital of Los Angeles (USA).

She has spent over two decades at the Tuberculosis Research Center in Chennai, South India (now renamed National Institute for Research in Tuberculosis) where she was the principal investigator for several clinical trials investigating treatment and prevention of TB among HIV-infected patients and was also involved in many collaborative operational, epidemiologic and behavioural research studies. These studies have had impact on TB and HIV policies both nationally and globally. She is currently Director of the institute, heads the NIH International Center for Excellence in Research in Chennai and continues to be actively involved in many clinical research projects. She has over 180 peer-reviewed publications, and serves on many high level national and international committees. Her major research interests are in pediatric and adult TB, their interaction with HIV and nutrition and management of co-infections, as well as pharmacokinetics and pharmacogenetics. She co-founded the Sentinel Project on Pediatric Drug Resistant TB in 2012 to advocate for increased global attention to this neglected group.

She is an elected Fellow of two of India’s Science Academies and chaired the HIV section of the International Union Against TB and Lung Diseases between 2011-13. She also served as Coordinator for Neglected Priorities Research at WHO/TDR, Geneva from 2009-2011 and is a member of the Scientific and Technical Advisory Group of the Global TB Department, WHO. She is the recipient of several national awards for excellence in biomedical sciences.
Dr Sten H. Vermund

Sten H. Vermund, MD, PhD, is an infectious disease epidemiologist and paediatrician. Dr. Vermund’s work is predominantly in the fields of HIV prevention, women’s and children’s health, and global health.

His work includes elucidating the relationship between HIV and HPV, illuminating the association and increased cervical disease risk in the late 1980s and co-developing major cervical cancer screening programs nested within HIV/AIDS programs in Africa and Asia in the 2000s. His HIV prevention and clinical research domestically and internationally has focused on issues of adolescent medicine and prevention of mother-to-child transmission, as well as women’s reproductive health and HIV.

Dr. Vermund has also helped forge the field of global health, including innovations in global research training, educational evaluation, and implementation science research. His bibliography includes over 460 peer-reviewed articles, book chapters, reviews, and reports. He is a member of the Institute of Medicine of the National Academy of Sciences, and serves on numerous organizational advisory committees, including the Scientific Technical Advisory Group of WHO’s Division of Reproductive Health and Research. Dr. Vermund serves as a Section Editor for PLOS ONE and on the journal editorial boards of JAIDS and AIDS, among others.

Affiliations
Vanderbilt University School of Medicine: Amos Christie Chair in Global Health, Professor of Pediatrics
Director: Vanderbilt Institute for Global Health
Harvard School of Public Health: Adjunct Professor of Epidemiology

Email
sten.vermund@vanderbilt.edu

Primary Areas of Expertise
Implementation Science
Prevention of mother-to-child transmission
Screening for Cervical cancer in resource-limited settings
Bruce D Walker, MD is the Director of the Ragon Institute of MGH, MIT and Harvard, a Professor of Medicine at Harvard Medical School, and a Howard Hughes Medical Institute Investigator.

In addition to his clinical duties as a board certified Infectious Disease specialist, his research focuses on cellular immune responses in chronic viral infections, with a particular focus on HIV. He leads an international translational clinical and basic science research effort to understand how some rare people who are infected with HIV, but have never been treated, can fight the virus with their immune system. Dr. Walker is also an Adjunct Professor at the Nelson Mandela School of Medicine in Durban, South Africa. There he collaborates with the Doris Duke Medical Research Institute at the University of KwaZulu-Natal and serves as a Principal Investigator in the HIV Pathogenesis Program, an initiative to study the evolution of the HIV and the immune responses effective in controlling this virus, as well as to contribute to training African scientists. He is a founding member of the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), a 10-year initiative funded by HHMI to build a state of the art TB-HIV research facility at the heart of these dual epidemics in South Africa. Dr. Walker is also a member of the American Academy of Arts and Sciences, American Society for Clinical Investigation, the American Association of Physicians, and the Institute of Medicine of the National Academy of Sciences.

**Affiliations**

**Director:** Ragon Institute of MGH, MIT and Harvard  
**Professor of Medicine:** Harvard Medical School  
**Howard Hughes Medical Institute Investigator**  
**Adjunct Professor:** Nelson Mandela School of Medicine in Durban, South Africa

**Email**

bwalker@mgh.harvard.edu

**Primary Areas of Expertise**

HIV Immunology  
Viral evolution under immune selection pressure
Helen Weiss joined the London School of Hygiene & Tropical Medicine (LSHTM) in 1997. Her research focuses on HIV epidemiology in sub-Saharan Africa, and she has played a leading role in the design and analysis of epidemiological studies of behavioural and biomedical HIV prevention strategies.

Studies have included the multicentre study of factors associated with the differential spread of HIV in sub-Saharan Africa, and randomized controlled trials of educational interventions, the impact of herpes suppressive therapy on HIV acquisition, and of episodic herpes treatment on HIV infectivity. Helen has a long-standing interest in global mental health research and is co-investigator on several trials evaluating the effectiveness and cost-effectiveness of lay health worker interventions to reduce morbidity from common mental disorders in India and Pakistan. She is particularly interested in interventions against mental disorders among HIV positive individuals.

Helen has co-authored more than 190 peer-reviewed scientific publications, including a series of systematic reviews on the role of male circumcision for HIV/STI prevention. Since January 2012, she has headed the MRC Tropical Epidemiology (TEG) at LSHTM, a group of around 30 statisticians and epidemiologists who work on a range of diseases of public health importance in low- and middle-income countries.
Brian Williams, PhD, is a South African epidemiologist who obtained his Ph.D. in physics at Cambridge University, England. After several years of research in solid state physics he moved into ecology and the control of tsetse flies and trypanosomiasis in Tanzania and Kenya, then at Oxford University and the London School of Hygiene and Tropical Medicine.

He returned to South Africa in 1994 to work on the epidemiology of occupational diseases of mine workers, mainly silicosis and tuberculosis. He ran a project to control HIV and AIDS in Carletonville, the biggest gold mining complex in the world, focusing on mine workers, sex workers and adolescents. He set up SACEMA, the South African Centre for Epidemiological Modelling and Analysis, based in Stellenbosch, South Africa, to develop analytical capacity in public health in Africa. He worked for ten years at the World Health Organization in Geneva on TB and HIV. He was the senior author on two key modelling papers that demonstrated the impact that anti-retroviral therapy could have on the epidemic of HIV and on the epidemic of HIV-related TB in Africa. After retiring from WHO he returned to South Africa where he continues to do consulting work for WHO, UNAIDS and SACEMA.

Dr Brian Williams

Affiliations
SACEMA, Stellenbosch, South Africa

Email
williamsbg@me.com; +27 76 134 2852

Primary Areas of Expertise
Epidemiology, statistics, mathematics
Dr Zunyou Wu

Zunyou Wu, MD, PhD, is the Director of the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. He graduated from UCLA with PhD in Epidemiology in 1995 with support of the Fogarty Program.

Dr. Wu conducts operational, scientific research and disseminates his research findings by organizing national workshops and developing national technical guidelines. He is a leader in the field of HIV prevention strategies and oversees the overall implementation of detection, prevention and treatment of HIV/AIDS in China. Dr. Wu designed, initiated and scaled up methadone maintenance treatment (MMT) and needle exchange program for drug users in China.

His current research includes cluster randomised trials of promoting integration of MMT and antiretroviral therapy among HIV infected opioid drug users to reduce their mortality, improved ways of helping MMT clients retain in treatment, studies to assess and disseminate best practice in harm reduction programs, innovative strategies to promote HIV test and treat among men who have sex with men, and promotion condom use and antiretroviral treatment among HIV discordant couples.

Affiliations
Director: National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention

Email
wuzy@263.net

Primary Areas of Expertise
Epidemiology
TB-HIV
HIV Prevention